Value through Innovation17 January 2013
Corporate Profile
  • Home
  • Search Result

Page content

jump to main navigation jump to meta navigation

Your search results.

  1. Hach T, Lambers Heerspink HJ, Pfarr E, Lund SS, Ley L, Broedl UC, Woerle HJ Phase II (1245.9,.10 pooled analysis; encore of EASD 2012)

    Hach T, Lambers Heerspink HJ, Pfarr E, Lund SS, Ley L, Broedl UC, Woerle HJ Phase II (1245.9,.10 pooled analysis; encore of EASD 2012)

    • Size: 180 kB
    • Last Update: 6.11.2012

  2. Macha S, Rose P, Mattheus M, Cinca R, Pinnetti S, Broedl UC, Woerle HJ Phase I (1245.13; encore of ADA 2012) The effect of hepatic impairment on the pharmacokinetics, safety and tolerability of empagliflozin, a potent sodium glucose cotransporter 2 inhibitor

    Macha S, Rose P, Mattheus M, Cinca R, Pinnetti S, Broedl UC, Woerle HJ Phase I (1245.13; encore of ADA 2012) The effect of hepatic impairment on the pharmacokinetics, safety and tolerability of empagliflozin, a potent sodium glucose cotransporter 2 inhibitor

    • Size: 214 kB
    • Last Update: 6.11.2012

  3. Heise T, Macha S, Mattheus M, Woerle HJ, Broedl UC Phase I (1245.42 PK data; encore of ADA 2012) Lack of interaction between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes

    Heise T, Macha S, Mattheus M, Woerle HJ, Broedl UC Phase I (1245.42 PK data; encore of ADA 2012) Lack of interaction between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes

    • Size: 231 kB
    • Last Update: 6.11.2012

  4. 04 Aug 2011 dabigatran

    First novel blood thinner in 50 years for the prevention of strokes caused by common heart rhythm disorder, approved inEurope

    • Size: 22 kB
    • Last Update: 5.11.2012

  5. 04 Aug 2011 dabigatran etexilate

    Breakthrough therapy PRADAXA (daibgatran etexilate) first drug in 50 years to gain approval for stroke prevention in atrial firillation in Europe

    • Size: 20 kB
    • Last Update: 5.11.2012

  6. 06 November2012 Dabigatran etexilate

    Safety and efficacy of Pradaxa® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement

    • Size: 14 kB
    • Last Update: 6.11.2012

  7. 05 November 2012 Dabigatran

    FDA and EMA reaffirm important health benefits and safety of Pradaxa® (dabigatran etexilate) for patients with atrial fibrillation

    • Size: 22 kB
    • Last Update: 6.11.2012

  8. 05 November 2012 Dabigatran etexilate

    Pradaxa®- Development of antidote may expand range of methods to reverse anticoagulant effect during emergency situations

    • Size: 23 kB
    • Last Update: 6.11.2012

  9. 08 November 2012 Dabigatran etexilate

    RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa® for stroke prevention in AF

    • Size: 22 kB
    • Last Update: 7.11.2012

  10. 08 November 2012 Linagliptin

    CAROLINA, a head-to-head cardiovascular outcome study comparing Trajenta® (linagliptin) with glimepiride completes recruitment

    • Size: 14 kB
    • Last Update: 7.11.2012
back to top